X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2926) 2926
heptanoic acids - therapeutic use (2774) 2774
atorvastatin calcium (2748) 2748
pyrroles - therapeutic use (2669) 2669
male (2280) 2280
female (1906) 1906
middle aged (1660) 1660
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1545) 1545
atorvastatin (1519) 1519
aged (1165) 1165
anticholesteremic agents - therapeutic use (1104) 1104
statins (1034) 1034
adult (869) 869
heptanoic acids - pharmacology (834) 834
treatment outcome (801) 801
pyrroles - pharmacology (773) 773
cholesterol (735) 735
cardiac & cardiovascular systems (734) 734
animals (692) 692
cholesterol, ldl - blood (689) 689
heptanoic acids - administration & dosage (647) 647
simvastatin (635) 635
pyrroles - administration & dosage (633) 633
pharmacology & pharmacy (596) 596
hypercholesterolemia - drug therapy (559) 559
simvastatin - therapeutic use (476) 476
pravastatin (469) 469
risk factors (450) 450
double-blind method (426) 426
atherosclerosis (420) 420
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (418) 418
heptanoic acids - adverse effects (415) 415
pyrroles - adverse effects (399) 399
cholesterol - blood (389) 389
drug therapy, combination (361) 361
peripheral vascular disease (358) 358
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (354) 354
triglycerides - blood (346) 346
hypercholesterolemia (338) 338
rats (334) 334
dose-response relationship, drug (332) 332
prospective studies (332) 332
prevention (331) 331
risk (330) 330
inflammation (317) 317
medicine, general & internal (317) 317
antilipemic agents (316) 316
cholesterol, hdl - blood (315) 315
lipids (308) 308
time factors (305) 305
pravastatin - therapeutic use (296) 296
lipids - blood (290) 290
disease (277) 277
hyperlipidemias - drug therapy (277) 277
therapy (271) 271
drug therapy (265) 265
coronary-heart-disease (259) 259
c-reactive protein (257) 257
hypercholesterolemia - blood (251) 251
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (249) 249
analysis (246) 246
rosuvastatin calcium (246) 246
follow-up studies (240) 240
cardiovascular (237) 237
statin (236) 236
anticholesteremic agents - administration & dosage (228) 228
cardiovascular disease (224) 224
research (222) 222
mice (221) 221
care and treatment (218) 218
aged, 80 and over (212) 212
anticholesteremic agents - pharmacology (211) 211
coronary heart disease (204) 204
expression (203) 203
hypolipidemic agents - therapeutic use (203) 203
myocardial-infarction (202) 202
efficacy (198) 198
randomized controlled trials as topic (197) 197
fluorobenzenes - therapeutic use (196) 196
sulfonamides - therapeutic use (195) 195
cardiovascular diseases - prevention & control (194) 194
biomarkers - blood (192) 192
cardiovascular-disease (191) 191
pyrimidines - therapeutic use (188) 188
cardiovascular agents (187) 187
anticholesteremic agents - adverse effects (184) 184
safety (182) 182
abridged index medicus (181) 181
endocrinology & metabolism (178) 178
disease models, animal (176) 176
statin therapy (175) 175
dyslipidemias - drug therapy (174) 174
low density lipoproteins (172) 172
mortality (171) 171
events (169) 169
rosuvastatin (168) 168
coronary artery disease - drug therapy (164) 164
medicine & public health (163) 163
coa reductase inhibitors (162) 162
coronary disease - drug therapy (160) 160
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3318) 3318
German (62) 62
Chinese (46) 46
Russian (37) 37
Japanese (36) 36
Spanish (32) 32
French (23) 23
Italian (10) 10
Portuguese (7) 7
Polish (6) 6
Hungarian (5) 5
Turkish (4) 4
Ukrainian (3) 3
Czech (2) 2
Dutch (2) 2
Danish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacological research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including Alzheimer disease... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | OXIDATIVE STRESS | COA REDUCTASE INHIBITORS | CLINICAL-TRIAL COHORT | DRUG-INTERACTIONS | NITRIC-OXIDE SYNTHASE | MILD COGNITIVE IMPAIRMENT | CELL-DEATH | COENZYME Q | AMYLOID-BETA | PHARMACOLOGY & PHARMACY | AUTOIMMUNE-DISEASE | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
MEDICINE, GENERAL & INTERNAL | EVENTS | MYOCARDIAL-INFARCTION | CHOLESTEROL | EFFICACY | ATHEROSCLEROSIS | PREVENTION | INTRAVASCULAR ULTRASOUND | PRAVASTATIN | ROSUVASTATIN | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Atorvastatin | Heart diseases | Lipoproteins (high density) | Ultrasound | Statins
Journal Article
The American heart journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 682 - 689.e1
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 08/2004, Volume 110, Issue 9, pp. 1061 - 1068
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 1, pp. 13 - 22
In this trial, 947 patients with renal-artery stenosis were assigned to renal-artery stenting or medical therapy. At a median of 43 months, there was no... 
MEDICINE, GENERAL & INTERNAL | REVASCULARIZATION | SYSTOLIC BLOOD-PRESSURE | PLACEMENT | PREVENTION | BALLOON ANGIOPLASTY | PREVALENCE | HYPERTENSION | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Hypertension - drug therapy | Male | Renal Insufficiency, Chronic - complications | Renal Artery | Treatment Failure | Cardiovascular Diseases - mortality | Female | Angioplasty, Balloon | Pyrroles - therapeutic use | Stents | Cardiovascular Diseases - etiology | Renal Artery Obstruction - drug therapy | Kaplan-Meier Estimate | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Amlodipine - therapeutic use | Renal Artery Obstruction - complications | Anticholesteremic Agents - therapeutic use | Hypertension - complications | Aged | Renal Artery Obstruction - therapy | Drug Combinations | Prevention | Evaluation | Care and treatment | Usage | Atherosclerosis | Therapeutics | Stent (Surgery) | Homeopathy | Materia medica and therapeutics | Hypertension | Myocardial infarction | Cerebral infarction | Stroke | Kidneys | Renal artery | Antihypertensives | Medical treatment | Clinical trials | Stenosis | Cardiovascular disease | Congestive heart failure | Renal insufficiency | Arteriosclerosis | Implants | Renal failure | Blood pressure | Kidney diseases | Geriatrics
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | INFLAMMATION | CARDIOVASCULAR-DISEASE | MARKERS | RISK | ACUTE CORONARY SYNDROMES | PRAVASTATIN | PRIMARY PREVENTION | PREDICTION | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins
Journal Article
The American journal of cardiology, ISSN 0002-9149, 2003, Volume 92, Issue 2, pp. 152 - 160
Journal Article
European heart journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | REDUCTASE INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ABCB1 | GENETIC-VARIANTS | CYP2C19 | CYTOCHROME-P450 3A4 | CLINICAL PHARMACOGENETICS | DRUG-DRUG INTERACTION | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
American Journal of Cardiovascular Drugs, ISSN 1175-3277, 04/2010, Volume 10, Issue 2, pp. 73 - 84
... mellitus.Objective To evaluate the efficacy and safety of fenofibric acid + statin combination therapy... 
Dyslipidaemias, treatment | HMG-CoA-reductase-inhibitors, therapeutic use | Fenofibrate, therapeutic use | Peroxisome-proliferator-activated-receptor-alpha-a | Diabetes-mellitus, treatment | Rosuvastatin, therapeutic use | Simvastatin, therapeutic use | Atorvastatin, therapeutic use | Pharmacotherapy | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | ABT-335 | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | CARDIOVASCULAR EVENTS | RISK | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | COMBINATION | SIMVASTATIN | INTERVENTION | ROSUVASTATIN | PARTICIPANTS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - therapeutic use | Simvastatin - adverse effects | Dyslipidemias - complications | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Dose-Response Relationship, Drug | Clinical Trials, Phase III as Topic | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Diabetes Mellitus, Type 2 - complications | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Double-Blind Method | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Fenofibrate - administration & dosage | Fenofibrate - analogs & derivatives | Rosuvastatin Calcium | Randomized Controlled Trials as Topic | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Hypolipidemic Agents - therapeutic use | Fluorobenzenes - therapeutic use | Sulfonamides - administration & dosage | Fenofibrate | Dyslipidemias | Patient outcomes | Dosage and administration | Drug therapy, Combination | Research | Drug therapy | Health aspects | Statins
Journal Article